| Sep 5 |
Adlai Nortye Ltd. (NASDAQ:ANL) stock most popular amongst retail investors who own 42%, while employee share scheme hold 29%
|
| Aug 9 |
Adlai Nortye reports 1H results
|
| Aug 8 |
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
|
| Aug 8 |
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
|
| May 24 |
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
|
| May 22 |
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
|
